Anterios Overview

  • Founded
  • 2006

Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 11

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $478M

Anterios General Information

Description

Developer of botulinum products for therapeutic and aesthetic applications. The company is a privately held, clinical-stage bio-pharmaceutical company that is developing next-generation botulinum-based prescription products for medical dermatology and aesthetic medicine.

Contact Information

Formerly Known As
Encapsion
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Other Pharmaceuticals and Biotechnology
Biotechnology
Acquirer
Primary Office
  • 60 East 42nd Street
  • Suite 1160
  • New York, NY 10165
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Anterios Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 06-Jan-2016 $478M 000.00 00000 Completed Product Development
6. IPO 30-Apr-2015 000.00 00000 Cancelled Product Development
5. Later Stage VC (Series B3) 24-Apr-2013 00.000 000.00 00000 Completed Startup
4. Early Stage VC (Series B3) 25-Jul-2011 00.000 000.00 000.00 Completed Startup
3. Early Stage VC (Series B2) 29-Dec-2010 00.00 000.00 00000 Completed Startup
2. Early Stage VC (Series B) 30-Nov-2009 $7.78M $15.3M 000.00 Completed Startup
1. Early Stage VC (Series A) 26-Jan-2007 $7.5M $7.5M 000.00 Completed Startup
To view Anterios’s complete valuation and funding history, request access »

Anterios Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B3 000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series B2 000,000 00.000000 00 000 000 00 000 0.000
Series B 1,136,466 $0.000100 8% $8.8 $8.8 1x $8.8 8.27%
Series A 2,529,425 $0.000100 8% $2.97 $2.97 1x $2.97 23.67%
To view Anterios’s complete cap table history, request access »

Anterios Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of botulinum products for therapeutic and aesthetic applications. The company is a privately held, clinical-st
Pharmaceuticals
New York, NY
11 As of 2016
000.00
0000 0000-00-00
000000&0 000.00

00000

tur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna
000000000000000
Basel, Switzerland
000000 As of 0000
000.00
000000000000 000.00

0000 0

enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip
000000000000000
Bagsvaerd, Denmark
00000 As of 0000
000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Anterios Competitors (28)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Roche Corporation Basel, Switzerland 000000 000.00 000000000000 000.00
0000 0000000 Corporation Bagsvaerd, Denmark 00000 000000000
000000 Corporation North Chicago, IL 00000 000.00 00000000000 000.00
00000 Formerly PE-Backed Chuncheon, South Korea 000 00000 00000000000 00000
0000 0000000000000 Corporate Backed or Acquired Petah Tikva, Israel 00000 000.00 000000000 00 000.00
You’re viewing 5 of 28 competitors. Get the full list »

Anterios Patents

Anterios Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2015252947-B2 Demonstrable efficacy across or within patient populations Active 01-May-2014 00000000000
AU-2020250248-A1 Demonstrable efficacy across or within patient populations Inactive 01-May-2014 00000000000
AU-2015252947-A1 Demonstrable efficacy across or within patient populations Active 01-May-2014 00000000000
CA-2947603-A1 Demonstrable efficacy across or within patient populations Inactive 01-May-2014 00000000000
EP-3137055-A4 Demonstrable efficacy across or within patient populations Inactive 01-May-2014 A61K38/4893 0
To view Anterios’s complete patent history, request access »

Anterios Executive Team (5)

Name Title Board Seat Contact Info
Jonathan Edelson MD Chief Executive Officer & Chairman
Klaus Theobald Ph.D Chief Research & Development Officer
You’re viewing 2 of 5 executive team members. Get the full list »

Anterios Board Members (5)

Name Representing Role Since
Jonathan Edelson MD Anterios Chief Executive Officer & Chairman 000 0000
You’re viewing 1 of 5 board members. Get the full list »

Anterios Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Anterios Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Colt Ventures Family Office Minority 000 0000 000000 0
DRW Venture Partners Corporate Venture Capital Minority 000 0000 000000 0
Praesideo Management Hedge Fund Minority 000 0000 000000 0
Quantum Technology Partners Venture Capital Minority 000 0000 000000 0
Scientific Health Development Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

Anterios Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000000 00 20-Apr-2017 00000 0000 00.000 Other Healthcare Technology Systems
To view Anterios’s complete investments history, request access »